RNS Number : 1893V
ValiRx PLC
30 January 2025

30 January 2025

ValiRx PLC
("ValiRx" or the "Company")

Extension of Evaluation Agreement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update on the Evaluation Agreement with the University of Dundee and their Drug Discovery Unit announced on 12 February 2024.

The Evaluation Agreement under the Overarching agreement with Dundee University focuses on investigating a lead series of therapeutic candidates in the increasingly important research area of pro-senescence (selectively promoting ageing of cancer cells to cease growth in tumours).

The evaluation process for this project in the Inaphaea BioLabs facility continues to demonstrate activity but specialist techniques are required to complete the mechanism of action studies. ValiRx have agreed a one year extension with the University of Dundee until 9 February 2026 to continue the mechanism of action studies which will be provided by the research group of Professor Cleo Bishop (Professor of Senescence and Director of the Queen Mary University London Phenotypic Screening Facility), supported by a £50,000 grant from the Queen Mary University London Impact Fund and £9,000 from ValiRx.

The Directors of the Company take responsibility for this announcement.

Mark Eccleston, CEO of ValiRx commented *"We are pleased with the demonstration of activity for the compounds under evaluation in Inaphaea's lab. A key decision point for in-licensing the asset is determination of the precise mechanism of action of the asset which requires access to techniques and equipment that we do not currently possess. We are fortunate to be working with Professor Bishop and have worked with her to secure non-dilutive funding to undertake the required work."*

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investorhub here:https://valirx.com/s/cc8ef3

For more information, please contact:

Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub	https://valirx.com/link/DP4BGe
ValiRx plc Dr Mark Eccleston, CEO	**Tel: +44 115 784 0025** www.valirx.com Mark.Eccleston@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**

Shard Capital Partners LLP (Sole Broker) Damon Heath	**Tel: +44 (0) 20 7186 9000**
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	**+44 (0) 115 787 0206** www.vformation.biz lucy@vformation.biz sue@vformation.biz

Subscribe to our news alert service:https://valirx.com/s/f298d1

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit:www.valirx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDSEIFAUEISEFF